FKFotios Koskeridis

Fotios Koskeridis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Fotios Koskeridis has a total of 171 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Proteogenomic Clustering of Multiple Long-Term Conditions Identifies Shared Immune Pathways and Candidate Therapeutic Targets

    by Xinzhu Yu, Alexander G. Smith, Rui Pinot, James Yarmolinsky, Fotios Koskeridis, Paul Elliott, Ioanna Tzoulaki, Abbas Dehghan

    Background: The co-occurrence of multiple long-term conditions (MLTCs) suggests shared aetiology, yet the underlying biology remains poorly characterised. Plasma proteomics combined with genetic causal inference enables investigation of protein-mediated pathways common to multiple diseases. Methods: We performed cis-acting protein quantitative trait loci (cis-pQTL) Mendelian randomisation (MR) on 2,034 plasma proteins (Olink, UK Biobank), estimating their effects on 71 complex traits spanning cardiovascular, neurological, psychiatric, inflammatory, and ageing-related domains. Traits were clustered based on their protein profiles, followed by cluster-level protein enrichment and pathway analyses. We integrated observational associations in UKB, genetic colocalisation, and drug-target databases to prioritise candidate shared therapeutic targets. Findings: Clustering identified 15 trait groupings with coherent biological processes, with immune-related pathways emerging as a central axis across autoimmune, cardiovascular, and neurodegenerative clusters. Across clusters, we prioritised 88 candidate shared therapeutic targets with varying levels of supporting evidence. Diseases within the same cluster share more approved and investigational drugs than diseases in different clusters, providing independent pharmacological support for these groupings.Interpretation: Our findings support a complementary view of MLTCs in which clinically distinct diseases can be reorganised by shared upstream protein biology. This represents a framework for hypothesis generation rather than definitive disease classification, providing a structured basis for prioritising proteins for functional validation and identifying drug repurposing opportunities.

  • Open Access

    Genome-Wide Pleiotropy Analysis Identifies Shared and Opposing Pathways Influencing Coronary Artery Disease and Cancer

    by James Yarmolinsky, Evelyn Lau, Fotios Koskeridis, Marc J. Gunter, Dennis Wang, Abbas Dehghan, Ioanna Tzoulaki

    BACKGROUND: Coronary artery disease (CAD) and cancer are 2 leading global causes of mortality, with shared modifiable risk factors, yet the genetic and molecular mechanisms underlying their comorbidity remain poorly understood. METHODS: We performed a genome-wide pleiotropy analysis to identify shared genetic mechanisms across CAD and 4 common cancers that share modifiable risk factors with CAD (breast, colorectal, lung, prostate). RESULTS: Using genome-wide pleiotropy and colocalization analysis, we identified 60 colocalized susceptibility loci shared by CAD and site-specific cancer, of which 43 are novel, including loci at TERT , MYO9B , and SREBF1 . For 35 loci, the lead SNP (single-nucleotide polymorphism) exhibited opposing effects on CAD and cancer risk. Gene-set enrichment analysis revealed distinct enrichment patterns of same-direction and opposing-direction pleiotropic loci, including differential associations with blood pressure–related traits, blood cell traits, and waist circumference. By integrating transcriptomic and proteomic data in multitrait colocalization, 13 pleiotropic loci influenced CAD and cancer risk via differential gene or protein expression of neighboring genes, including CALCRL , ANGPTL4 , and LAMC1 , targets of approved or investigational medications. Phenome-wide association analysis in the UK Biobank identified 1955 associations (false discovery rate [FDR] P <0.05) of lead SNPs at multitrait colocalized loci with serum biomarkers and clinical measures, with apoA, HDL (high-density lipoprotein) cholesterol, and creatinine being associated with the largest number of lead SNPs. CONCLUSIONS: Our findings highlight shared and opposing genetic loci between CAD and cancer and provide insight into molecular intermediates mediating joint disease risk. Importantly, they indicate potential drug repurposing opportunities for dual CAD and cancer prevention while highlighting possible adverse and divergent effects of existing medications across both conditions.


  • Open Access

    Multi-trait association analysis reveals shared genetic loci between Alzheimer’s disease and cardiovascular traits

    by Fotios Koskeridis, Nurun Fancy, Pei Fang Tan, Devendra Meena, Evangelos Evangelou, Paul Elliott, Dennis Wang, Paul M. Matthews, Abbas Dehghan, Ioanna Tzoulaki

    Several cardiovascular traits and diseases co-occur with Alzheimer’s disease. We mapped their shared genetic architecture using multi-trait genome-wide association studies. Subsequent fine-mapping and colocalisation highlighted 16 genetic loci associated with both Alzheimer’s and cardiovascular diseases. We prioritised rs11786896, which colocalised with Alzheimer’s disease, atrial fibrillation and expression of PLEC in the heart left ventricle, and rs7529220, which colocalised with Alzheimer’s disease, atrial fibrillation and expression of C1Q family genes. Single-cell RNA-sequencing data, co-expression network and protein-protein interaction analyses provided evidence for different mechanisms of PLEC, which is upregulated in left ventricular endothelium and cardiomyocytes with heart failure and in brain astrocytes with Alzheimer’s disease. Similar common mechanisms are implicated for C1Q in heart macrophages with heart failure and in brain microglia with Alzheimer’s disease. These findings highlight inflammatory and pleomorphic risk determinants for the co-occurrence of Alzheimer’s and cardiovascular diseases and suggest PLEC, C1Q and their interacting proteins as potential therapeutic targets.


  • Open Access

    Pleiotropic effects of PLEC and C1Q on Alzheimer’s disease and cardiovascular traits

    by Fotios Koskeridis, Nurun Fancy, Pei Fang Tan, Evangelos Evangelou, Devendra Meena, Paul Elliott, Dennis Wang, Paul Matthews, Abbas Dehghan, Ioanna Tzoulaki

    Several cardiovascular (CV) traits and diseases co-occur with Alzheimer’s disease (AD). We mapped their shared genetic architecture using multi-trait genome-wide association studies. Subsequent fine-mapping and colocalisation highlighted 19 genetic loci associated with both AD and CV diseases. We prioritised rs11786896, which colocalised with AD, atrial fibrillation (AF) and expression of PLEC in the heart left ventricle, and rs7529220, which colocalised with AD, AF and expression of C1Q family genes. Single-cell RNA-sequencing data, co-expression network and protein-protein interaction analyses provided evidence for different mechanisms of PLEC, which is upregulated in left ventricular endothelium and cardiomyocytes with heart failure (HF) and in brain astrocytes with AD. Similar common mechanisms are implicated for C1Q in heart macrophages with HF and in brain microglia with AD. These findings highlight inflammatory and pleomorphic risk determinants for the co-occurrence of AD and CV diseases and suggest PLEC, C1Q and their interacting proteins as novel therapeutic targets.

  • Open Access

    Associations of genetically predicted fatty acid levels across the phenome: A mendelian randomisation study

    by Loukas Zagkos, Marie-Joe Dib, Rui Pinto, Dipender Gill, Fotios Koskeridis, Fotios Drenos, Georgios Markozannes, Paul Elliott, Verena Zuber, Kostas Tsilidis, et al.

    Background: Fatty acids are important dietary factors that have been extensively studied for their implication in health and disease. Evidence from epidemiological studies and randomised controlled trials on their role in cardiovascular, inflammatory, and other diseases remains inconsistent. The objective of this study was to assess whether genetically predicted fatty acid concentrations affect the risk of disease across a wide variety of clinical health outcomes.Methods and findings: The UK Biobank (UKB) is a large study involving over 500,000 participants aged 40 to 69 years at recruitment from 2006 to 2010. We used summary-level data for 117,143 UKB samples (base dataset), to extract genetic associations of fatty acids, and individual-level data for 322,232 UKB participants (target dataset) to conduct our discovery analysis. We studied potentially causal relationships of circulating fatty acids with 845 clinical diagnoses, using mendelian randomisation (MR) approach, within a phenome-wide association study (PheWAS) framework. Regression models in PheWAS were adjusted for sex, age, and the first 10 genetic principal components. External summary statistics were used for replication. When several fatty acids were associated with a health outcome, multivariable MR and MR-Bayesian method averaging (MR-BMA) was applied to disentangle their causal role. Genetic predisposition to higher docosahexaenoic acid (DHA) was associated with cholelithiasis and cholecystitis (odds ratio per mmol/L: 0.76, 95% confidence interval: 0.66 to 0.87). This was supported in replication analysis (FinnGen study) and by the genetically predicted omega-3 fatty acids analyses. Genetically predicted linoleic acid (LA), omega-6, polyunsaturated fatty acids (PUFAs), and total fatty acids (total FAs) showed positive associations with cardiovascular outcomes with support from replication analysis. Finally, higher genetically predicted levels of DHA (0.83, 0.73 to 0.95) and omega-3 (0.83, 0.75 to 0.92) were found to have a protective effect on obesity, which was supported using body mass index (BMI) in the GIANT consortium as replication analysis. Multivariable MR analysis suggested a direct detrimental effect of LA (1.64, 1.07 to 2.50) and omega-6 fatty acids (1.81, 1.06 to 3.09) on coronary heart disease (CHD). MR-BMA prioritised LA and omega-6 fatty acids as the top risk factors for CHD. Although we present a range of sensitivity analyses to the address MR assumptions, horizontal pleiotropy may still bias the reported associations and further evaluation in clinical trials is needed.Conclusions: Our study suggests potentially protective effects of circulating DHA and omega-3 concentrations on cholelithiasis and cholecystitis and on obesity, highlighting the need to further assess them as prevention treatments in clinical trials. Moreover, our findings do not support the supplementation of unsaturated fatty acids for cardiovascular disease prevention.


  • Open Access

    Pleiotropic genetic architecture and novel loci for C-reactive protein levels

    by Fotios Koskeridis, Evangelos Evangelou, Saredo Said, Joseph J. Boyle, Paul Elliott, Abbas Dehghan, Ioanna Tzoulaki

    C-reactive protein is involved in a plethora of pathophysiological conditions. Many genetic loci associated with C-reactive protein are annotated to lipid and glucose metabolism genes supporting common biological pathways between inflammation and metabolic traits. To identify novel pleiotropic loci, we perform multi-trait analysis of genome-wide association studies on C-reactive protein levels along with cardiometabolic traits, followed by a series of in silico analyses including colocalization, phenome-wide association studies and Mendelian randomization. We find 41 novel loci and 19 gene sets associated with C-reactive protein with various pleiotropic effects. Additionally, 41 variants colocalize between C-reactive protein and cardiometabolic risk factors and 12 of them display unexpected discordant effects between the shared traits which are translated into discordant associations with clinical outcomes in subsequent phenome-wide association studies. Our findings provide insights into shared mechanisms underlying inflammation and lipid metabolism, representing potential preventive and therapeutic targets.


  • Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis

    by Fotios Koskeridis, Evangelos Evangelou, Evangelia E. Ntzani, Konstantinos Kostikas, Sophia Tsabouri

    Atopic dermatitis (AD) is a type 2 chronic skin disorder associated with systemic and psychosocial comorbidities decreasing the quality of life for many patients. Dupilumab, a human monoclonal antibody that blocks interleukins IL-4 and IL-13, is a recently added systematic treatment option with an emerging evidence base. Here, we assessed the safety and efficacy of dupilumab in patients with AD. We conducted a systematic review and meta-analysis of placebo-controlled randomized clinical trials evaluating the safety and efficacy of dupilumab on AD-related outcomes including clinical symptoms, quality of life and adverse events (AE). Subgroup analysis was further performed in adults and children/adolescents. Fourteen trials were included: twelve in adults (n = 3,817) and two in children/adolescents (n = 618). Dupilumab decreased the Eczema Area Severity Index (EASI) score [standardized mean difference (SMD) = −0.98; 95% confidence interval (95% CI) = (−1.09, −0.88)], the percent change difference in Scoring Atopic Dermatitis (SCORAD) [mean difference (MD) = −31.56, 95% CI = (−33.75, −29.36)], and in pruritus Numeric Rating Scale (pNRS) [MD = −29.24, 95% CI = (−32.11, −26.37)]. It also achieved a reduction of at least ≥75% in the EASI score [Risk Ratio (RR) = 2.89, 95% CI = (2.47, 3.38)], the Investigator’s Global Assessment (IGA) score ≤1 [RR = 3.47, 95% CI = (2.96, 4.06)] and eight additional endpoints with no signs of increased AE compared to placebo. In subgroup analysis, the results were concordant for both groups. Dupilumab improved clinical symptoms and quality of life in adults and children/adolescents with a safety profile comparable to placebo.


  • Open Access

    Author Correction: Genetic analysis of over half a million people characterises C-reactive protein loci

    by Saredo Said, Raha Pazoki, Ville Karhunen, Urmo Võsa, Symen Ligthart, Barbara Bodinier, Fotios Koskeridis, Paul Welsh, Behrooz Z. Alizadeh, Daniel I. Chasman, et al.


  • Top Cited Papers
    Open Access

    Genetic analysis of over half a million people characterises C-reactive protein loci

    by Saredo Said, Raha Pazoki, Ville Karhunen, Urmo Võsa, Symen Ligthart, Barbara Bodinier, Fotios Koskeridis, Paul Welsh, Behrooz Z. Alizadeh, Daniel I. Chasman, et al.

    Chronic low-grade inflammation is linked to a multitude of chronic diseases. We report the largest genome-wide association study (GWAS) on C-reactive protein (CRP), a marker of systemic inflammation, in UK Biobank participants (N = 427,367, European descent) and the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium (total N = 575,531 European descent). We identify 266 independent loci, of which 211 are not previously reported. Gene-set analysis highlighted 42 gene sets associated with CRP levels (p ≤ 3.2 ×10−6) and tissue expression analysis indicated a strong association of CRP related genes with liver and whole blood gene expression. Phenome-wide association study identified 27 clinical outcomes associated with genetically determined CRP and subsequent Mendelian randomisation analyses supported a causal association with schizophrenia, chronic airway obstruction and prostate cancer. Our findings identified genetic loci and functional properties of chronic low-grade inflammation and provided evidence for causal associations with a range of diseases.


  • Open Access

    Candidate genetic variants and antidepressant-related fall risk in middle-aged and older adults

    by A. C. Pronk, L. J. Seppala, K. Trajanoska, N. Stringa, B. van de Loo, L. C. P. G. M. de Groot, N. M. van Schoor, F. Koskeridis, G. Markozannes, E. Ntzani, et al.

    Background: Antidepressant use has been associated with increased fall risk. Antidepressant-related adverse drug reactions (e.g. orthostatic hypotension) depend partly on genetic variation. We hypothesized that candidate genetic polymorphisms are associated with fall risk in older antidepressant users. Methods: The association between antidepressant use and falls was cross-sectionally investigated in a cohort of Dutch older adults by logistic regression analyses. In case of significant interaction product term of antidepressant use and candidate polymorphism, the association between the variant genotype and fall risk was assessed within antidepressant users and the association between antidepressant use and fall risk was investigated stratified per genotype. Secondly, a look-up of the candidate genes was performed in an existing genome-wide association study on drug-related falls in antidepressant users within the UK Biobank. In antidepressant users, genetic associations for our candidate polymorphisms for fall history were investigated. Results: In antidepressant users(n = 566), for rs28371725 (CYP2D6*41) fall risk was decreased in TC/variant allele carriers compared to CC/non-variant allele carriers (OR = 0.45, 95% CI 0.26–0.80). Concerning rs1057910 (CYP2C9*3), fall risk was increased in CA/variant allele carriers compared to AA/non-variant allele carriers (OR = 1.95, 95% CI 1.17–3.27). Regarding, rs1045642 (ABCB1), fall risk was increased in AG/variant allele carriers compared to GG/non-variant allele carriers (OR = 1.69, 95% CI 1.07–2.69). Concerning the ABCB1-haplotype (rs1045642/rs1128503), fall risk was increased in AA-AA/variant allele carriers compared to GG-GG/non-variant allele carriers (OR = 1.86, 95% CI 1.05–3.29). In the UK Biobank, in antidepressant users(n = 34,000) T/variant-allele of rs28371725 (CYP2D*41) was associated with increased fall risk (OR = 1.06, 95% CI 1.01–1.12). G/non-variant-allele of rs4244285 (CY2C19*2) was associated with decreased risk (OR = 0.96, 95% CI 0.92–1.00). Conclusion: This is the first study showing that certain genetic variants modify antidepressant-related fall risk. The results were not always consistent across the studies and should be validated in a study with a prospective design. However, pharmacogenetics might have value in antidepressant (de)prescribing in falls prevention.